The benefit of beta-blockers in the management of patients with heart failure and left ventricular dysfunction has been incontrovertibly established in multiple contemporary randomized clinical trials (1–5). The recommendation for use of beta-blockers after acute myocardial infarction (MI) is mainly based on studies (6–8) that predate routine implementation of a contemporary strategy of early reperfusion and modern medical therapy, although some observational data suggest that beta-blocker therapy may be associated with reduced long-term mortality after early percutaneous coronary intervention for acute MI (9,10).
Publication information
Steg PG, de Silva R. Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence? J Am Coll Cardiol, 2014;64:253-255